R&D | October 12, 2025
Merck unveils new HIV treatment and prevention data at EACS 2025
Merck will showcase results in innovative solutions in HIV treatment and prevention
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Subscribe To Our Newsletter & Stay Updated
